Cadrenal Therapeutics, Inc. (NasdaqCM: CVKD)
Health Care · Pharmaceuticals · US
$1.53
-4.97% today · -86.9% 1Y
Cadrenal Therapeutics, Inc. (NasdaqCM: CVKD) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $5.74M and employs 5 people.
Over the last twelve months the share price has lost 86.9%, trading between 1.54 and 14.64.
Tweenvest scores Cadrenal Therapeutics, Inc. across four factors: quality 26/100. Its strongest factor is quality.
CVKD price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $5.74M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -4.86
- Dividend yield
- —
- Beta (5Y)
- 1.86
- 52-week high
- $14.64
- 52-week low
- $1.54
- Avg volume (3M)
- —
- Shares outstanding
- 3.57M
- Employees
- 5
- Next earnings
- —
About Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics, Inc. operates as a biopharmaceutical enterprise primarily engaged in clinical development. The company's core focus is the advancement of Tecarfarin, a novel therapeutic agent that has received orphan drug designation. This treatment is engineered to prevent systemic thromboembolism originating from cardiac issues in patients suffering from both end-stage renal disease and atrial fibrillation. Established in 2022, the firm is headquartered in Ponte Vedra, Florida.
- ISIN
- US1276362076
- Founded
- 2022
- Listed since
- Jan 20, 2023
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.10T | $1,235.36 | +0.14% |
| Johnson & JohnsonNYSE: JNJ | $658.24B | $273.50 | +0.13% |
| Merck & Co., Inc.NYSE: MRK | $385.99B | $155.85 | -0.38% |
| Roche Holding AGSWX: ROP | $371.62B | CHF369.70 | -1.10% |
| Novartis AGSWX: NOVN | $303.81B | CHF128.34 | +1.25% |
| AstraZeneca PLCLSE: AZN | $263.84B | £122.92 | -1.47% |
| Novo Nordisk A/SCPSE: NOVO B | $212.51B | Dkr307.80 | +2.86% |
| Pfizer Inc.NYSE: PFE | $162.84B | $28.52 | -0.18% |
Figures last refreshed Aug 18, 2026.